Bone Biologics Corporation Statistics
Share Statistics
Bone Biologics Corporation has 2.46M shares outstanding. The number of shares has increased by -42.53% in one year.
| Shares Outstanding | 2.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 63.69% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.46M |
| Failed to Deliver (FTD) Shares | 1.61K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 72.06K, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 72.06K |
| Short % of Shares Out | 2.92% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 0.18 |
Valuation Ratios
The PE ratio is -0.13 and the forward PE ratio is -0.55.
| PE Ratio | -0.13 |
| Forward PE | -0.55 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.41 |
| P/FCF Ratio | -0.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Bone Biologics Corporation has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.08% and return on capital (ROIC) is -324.4%.
| Return on Equity (ROE) | -3.08% |
| Return on Assets (ROA) | -2.39% |
| Return on Capital (ROIC) | -324.4% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.47M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.7% in the last 52 weeks. The beta is 0.74, so Bone Biologics Corporation's price volatility has been higher than the market average.
| Beta | 0.74 |
| 52-Week Price Change | -63.7% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 1.65 |
| Relative Strength Index (RSI) | 39.33 |
| Average Volume (20 Days) | 3.10M |
Income Statement
In the last 12 months, Bone Biologics Corporation had revenue of $0 and earned -$8.95M in profits. Earnings per share was $-34.01.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -9.43M |
| Net Income | -8.95M |
| EBITDA | 479.57K |
| EBIT | - |
| Earnings Per Share (EPS) | -34.01 |
Balance Sheet
The company has $3.03M in cash and $0 in debt, giving a net cash position of $3.03M.
| Cash & Cash Equivalents | 3.03M |
| Total Debt | 0 |
| Net Cash | 3.03M |
| Retained Earnings | -80.91M |
| Total Assets | 4.07M |
| Working Capital | 3.79M |
Cash Flow
In the last 12 months, operating cash flow was -$9.56M and capital expenditures $0, giving a free cash flow of -$9.56M.
| Operating Cash Flow | -9.56M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.56M |
| FCF Per Share | -36.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BBLG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3091.82% |
| FCF Yield | -351.8% |
Analyst Forecast
Currently there are no analyst rating for BBLG.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 20, 2023. It was a backward split with a ratio of 1:8.
| Last Split Date | Dec 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -24.57 |
| Piotroski F-Score | 1 |